Raymond James Financial
MCRB icon

Raymond James Financial’s Seres Therapeutics MCRB Stock Holding History

Raymond James Financial’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-56
Closed -$623 – 5999
2025
Q2 		$623 Buy
+56
New +$493 ﹤0.01% 6643

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Raymond James Financial's MCRB Position: Q3 2025 in Review

Raymond James Financial sold out of Seres Therapeutics (MCRB) in Q3 2025, closing a stake of 56 shares — an estimated $623 sold.

Raymond James Financial first reported a position in MCRB in Q2 2025 and held it in 1 quarter. The position peaked at $623 in Q2 2025. 32 funds tracked by Wall St. Rank hold MCRB as of Q3 2025.

  • Raymond James Financial reported no remaining Seres Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 56 Seres Therapeutics shares in Q3 2025, an estimated $623.
  • Raymond James Financial first reported a position in Seres Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Seres Therapeutics position peaked at $623 in Q2 2025.
  • 32 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.